Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 495-501

  Rosales, Alexy ^a   Alvear, Marysol ^b   Cuevas, Alejandro ^a   Saavedra, Nicolás ^a   Zambrano, Tomaá ^a   Salazar, Luis A ^a  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Atorvastatin; CYP3A4; Hypercholesterolemia; Polymorphisms

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABCB1 GENE; ADULT; ARTICLE; CHILE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE PRODUCT; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CHILE; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; TREATMENT OUTCOME;

EID: 84355166408     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.003     Document Type: Article

References (54)

1. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438):937-952.
2. Medina E., Kaempffer A. Epidemiology of cardiovascular disease in Chile. Rev Chil Cardiol 2007, 26:219-226.
3. Luque C., Cisternas F.A., Araya M. Changes in the patterns of disease after the epidemiological transition in health in Chile, 1950-2003. Rev Med Chil 2006, 134(6):703-712.
4. Lanas F., Avezum A., Bautista L.E., et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007, 115(9):1067-1074.
5. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010, 87(1):130-133.
6. Kirmizis D., Chatzidimitriou D. Pleiotropic vasoprotective effects of statins: the chicken or the egg?. Drug Des Devel Ther 2009, 3:191-204.
7. Vaughan C.J., Gotto A.M., Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000, 35(1):1-10.
8. LaRosa J.C. Low-density lipoprotein cholesterol reduction: the end is more important than the means. Am J Cardiol 2007, 100(2):240-242.
9. Igel M., Sudhop T., Von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001, 57(5):357-364.
10. Galteau M.M., Shamsa F. Urinary 6ß-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003, 59(10):713-733.
11. Malinowski J.M. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm 1998, 55(21):2253-2267.
12. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80(6):565-581.
13. Voora D., Shah S.H., Reed C.R., et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008, 1(2):100-106.
14. Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001, 2:9-39.
15. Evans WE. Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut 2003; 52 (Suppl 2): ii10-18.
16. Salazar L.A., Hirata M.H., Quintao E.C., Hirata R.D. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 2000, 14(3):125-131.
17. Kajinami K, Akao H, Polisecki E, Schaefer EJ. Pharmacogenomics of statin responsiveness. Am J Cardiol 2005; 96(9A); 65K-70K.
18. Wang A., Yu B.N., Luo C.H., et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005, 60(12):843-848.
19. Kerola T., Lehtimáki T., Káhónen M., Nieminen T. Statin pharmacogenomics: lipid response and cardiovascular outcomes. Current Cardiovascular Risk Reports 2010, 4(2):150-158.
20. Cascorbi I., Gerloff T., Johne A., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001, 69(3):169-174.
21. Bodor M., Kelly E.J., Ho R.J. Characterization of the human MDR1 gene. AAPS J 2005, 7(1):E1-E5.
22. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002, 12(3):251-263.
23. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001, 31(8-9):469-497.
24. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004, 93(1):104-107.
25. Kim K.A., Park P.W., Lee O.J., Kang D.K., Park J.Y. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007, 47(1):87-93.
26. Rodrigues A.C., Rebecchi I.M., Bertolami M.C., Faludi A.A., Hirata M.H., Hirata R.D. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 2005, 38(9):1389-1397.
27. Mega J.L., Morrow D.A., Brown A., Cannon C.P., Sabatine M.S. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009, 29(9):1310-1315.
28. Amirimani B., Ning B., Deitz A.C., Weber B.L., Kadlubar F.F., Rebbeck T.R. Increased transcriptional activity of the CYP3A41B promoter variant. Environ Mol Mutagen 2003, 42(4):299-305.
29. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27(4):383-391.
30. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239.
31. Jaramillo P.C., Muñoz A., Lanas C., Lanas F., Salazar L.A. Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls. Clin Chim Acta 2006, 371(1-2):102-106.
32. Salazar L.A., Hirata M.H., Cavalli S.A., Machado M.O., Hirata R.D.C. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 1998, 44(8):1748-1750.
33. Cavalli S.A., Hirata M.H., Hirata R.D.C. Detection of MboII polymorphism at the 5' promoter region of CYP3A4. Clin Chem 2001, 47(2):348-351.
34. Hong Z., Yu F., Ying L., Aibin L. A highly sensitive SPE- liquid/liquid extraction-RPLC analytical method for the determination of 6[beta]-hydroxycortisol and cortisol in cancer patients' urine. Journal of Medical Colleges of PLA 2010, 25(2):75-83.
35. Romero T., Romero C.X. Stagnant in cardiovascular prevention: alarming trends and persistent socioeconomic obstacles. Rev Esp Cardiol 2010, 63(11):1340-1348.
36. Lagos J., Lemus J., Sierra F., et al. Association of serum lipid levels and mitochondrial DNA Amerindian haplogroups in hypercholesterolemic subjects receiving atorvastatin. Rev Chil Cardiol 2010, 29(2):208-213.
37. Cerda A., Genvigir F.D., Arazi S.S., et al. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. Clin Chim Acta 2010, 411(9-10):631-637.
38. Thompson J.F., Man M., Johnson K.J., et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005, 5(6):352-358.
39. Ball S.E., Scatina J., Kao J., et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 1999, 66(3):288-294.
40. Sata F., Sapone A., Elizondo G., et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000, 67(1):48-56.
41. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008, 392(6):1093-1108.
42. Hu Y.F., He J., Chen G.L., et al. CYP3A53 and CYP3A418 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005, 353(1-2):187-192.
43. Horinouchi M., Sakaeda T., Nakamura T., et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002, 19(10):1581-1585.
44. Kudzi W., Dodoo A.N., Mills J.J. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?. BMC Med Genet 2010, 11:111.
45. Dally H., Bartsch H., Jager B., et al. Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett 2004, 207(1):95-99.
46. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004, 93(8):1046-1050.
47. Wielandt A.M., Vollrath V., Chianale J. Polymorphisms of the multiple drug resistance gene (MDR1) in Mapuche, Mestizo and Maori populations in Chile. Rev Med Chil 2004, 132(9):1061-1068.
48. Yi S.Y., Hong K.S., Lim H.S., et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 2004, 76(5):418-427.
49. Ameyaw M.M., Regateiro F., Li T., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11(3):217-221.
50. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., Kennedy M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002, 2(3):191-196.
51. Gao Y., Zhang L.R., Fu Q. CYP3A41G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008, 64(9):877-882.
52. Poduri A., Khullar M., Bahl A., Sehrawat B.S., Sharma Y., Talwar K.K. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 2010, 29(10):629-637.
53. Kivisto K.T., Niemi M., Schaeffeler E., et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004, 14(8):523-525.
54. Lykkesfeldt J., Loft S., Poulsen H.E. Simultaneous determination of urinary free cortisol and 6 beta-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Appl 1994, 660(1):23-29.